Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677162 | 1.00 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL4641124 | 1.00 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL376154 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL995705 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2619553 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1562695 | 0.89 | PPARA (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7172323 | 0.89 | PPARA (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.89 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL21340066 | 0.89 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL13688643 | 0.89 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255684-A | CD4 enhancement+Compounds for T cell differentiation into Th9 cells | 广州医科大学 | 2024-06-28 | — | — | CN | disclosed |
| US-6974879-B2 | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1580191-A1 | PROCESS FOR PRODUCING CARBAPENEM COMPOUND FOR ORAL ADMINISTRATION | KANEKA CORPORATION (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050020683-A1 | Process for preparing single enantiomers of 5,5,5,5',5',5'-hexafluoroleucine and protected analogs | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2005-01-27 | — | — | US | disclosed |
| US-6787664-B2 | RADICAL DEOXYGENATION OF TERTIARY HYDROXY GROUP | WARNER-LAMBERT COMPANY LLC | 2004-09-07 | — | — | US | disclosed |
| US-20040110982-A1 | Process for preparing single enantiomers of 5,5,5,5',5',5'-hexafluoroleucine and protected analogs | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110982-A1 | Process for preparing single enantiomers of 5,5,5,5',5',5'-hexafluoroleucine and protected analogs | FABP5, PLAAT5, PLIN5 | SYK 4284/4885CTSK 3077/4885CTSS 2341/4885 |
| US-20050020683-A1 | Process for preparing single enantiomers of 5,5,5,5',5',5'-hexafluoroleucine and protected analogs | FABP5, PLAAT5, PLIN5 | SYK 4302/4885CTSK 3389/4885CTSS 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.